雾化吸入对 COPD 并糖尿病大鼠血糖变化及死亡率的影响

摘要

Objective:To study the glucose changes and mortality in diabetic rats with COPD of inhaling corticosteroids and short -acting β2 agonist .Methods:80 successful modeling diabetic rats with COPD were randomly divided into four groups of A ,B,C,D,n=20 in each group;there were the inhaled corticosteroids group, the inhaled short -acting β2 agonist group, the united inhaled glucocorticoids and short -acting β2 agonists group ,the saline control group;the atomization inhalation therapy in each group was for 15 minutes/time, 2 times/day;All groups were treated for 10 days.Results:The blood glucose control situation was no significant difference ( P>0.05 ) between the united glucocorticoid and short -actingβ2 receptor agonist group and other groups , but the the mortality in united inhalation group was lower than in -other groups ( P <0.05 ) .Conclusion:The United inhaled glucocorticoids and short -acting β2 agonist in treatment of diabetes with COPD have no effect on blood sugar control , and can more effectively enhance therapeutic levels , improve their prognosis and reduce mortality .%目的：研究联合使用吸入性糖皮质激素及短效β2受体兴奋剂治疗慢性阻塞性肺疾病（ COPD）并糖尿病大鼠，对大鼠血糖的变化以及死亡率的影响。方法：选取80只造模成功的COPD并糖尿病大鼠，随机分为A组、B组、C组、D组，每组各20只，分别给予单独吸入糖皮质激素治疗、单独吸入短效β2受体兴奋剂治疗、联合吸入糖皮质激素及短效β2受体兴奋剂治疗、生理盐水对照。各组大鼠雾化吸入治疗15 min/次，2次/d，疗程均为10 d。结果：联合吸入糖皮质激素及短效β2受体兴奋剂治疗的血糖控制情况与其他组比较无显著性差异（ P ＞0.05），但联合吸入治疗组死亡率较其他组低（ P ＜0.05）。结论：联合吸入糖皮质激素及短效β2受体兴奋剂治疗对COPD并糖尿病大鼠的血糖控制无影响，而且可以提高治疗水平，改善预后，降低死亡率。